Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPOX-Bevacizumab for Metastatic Neuroendocrine Tumors
NCT00398320Phase 2Completed
- Start
- Nov 2006
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin, bevacizumab in Neuroendocrine Neoplasm (NEN). Started Nov 2006; status: completed.
02
Drugs
capecitabineoxaliplatinbevacizumab
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00398320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00398320.